GPCR-targeting drugs
![Septerna Therapeutics, Vertex Pharmaceuticals, Licensing deals, GPCR, GPCR-targeting drugs, Cystic fibrosis](https://pharmtales.com/wp-content/uploads/2023/09/Vertex-partners-with-Septerna-to-develop-GPCR-targeting-drugs-for-rare-diseases.jpg)
Vertex partners with Septerna to develop GPCR-targeting drugs for rare diseases
Anika Sharma
Septerna, a biotech company, has secured an additional $47.5 million in funding through a licensing agreement with Vertex, a prominent ...